17-Ethylendioxy-3-methoxy-oestra-2,5(10)-dien | 1238-30-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 17-Ethylendioxy-3-methoxy-oestra-2,5(10)-dien
• 英文别名: 1,4-Dihydro-oestron-3-methylether-17-ethylenketal；17-Ethandiyldioxy-3-methoxy-oestra-2,5(10)-dien；Ethylenketal des 3-Methoxyestra-3,5(10)-dien-17-on；17,17-ethanediyldioxy-3-methoxy-estra-2,5(10)-diene；17,17-Aethandiyldioxy-3-methoxy-oestra-2,5(10)-dien；1,4-dihydroestron-3-methyl ether-17-ketal；(8'R,9'S,13'S,14'S)-3'-methoxy-13'-methylspiro[1,3-dioxolane-2,17'-4,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene]
• CAS: 1238-30-8
• 化学式: C₂₁H₃₀O₃
• 分子量: 330.467
• InChiKey: PAQSDDJPMUCLBU-ZRNYENFQSA-N

物化性质

• 熔点：
  129-130 °C
• 沸点：
  467.6±45.0 °C(Predicted)
• 密度：
  1.15±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  24
• 可旋转键数：
  1
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.81
• 拓扑面积：
  27.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  17-Ethylendioxy-3-methoxy-oestra-2,5(10)-dien 在 盐酸 、 乙醇 、 三溴甲烷 、 potassium tert-butylate 、 氨 、 lithium 、 对甲苯磺酸 作用下， 以 乙醚 、 氯仿 、 甲苯 为溶剂， 反应 2.5h， 生成 雄烯二酮
  参考文献：
  名称：

  [EN] METHODS FOR PREPARING SYNTHETIC BILE ACIDS AND COMPOSITIONS COMPRISING THE SAME
  [FR] MÉTHODES DE SYNTHÈSE D'ACIDES BILIAIRES SYNTHÉTIQUES ET COMPOSITIONS LES INCLUANT

  摘要：

  公开号：

  WO2012047495A3
• 作为产物：
  描述：

  3-甲氧基雌酮 在 三氟化硼乙醚 、 氨 、 lithium 、 原甲酸三乙酯 、 sodium hydroxide 作用下， 以 四氢呋喃 为溶剂， 反应 6.75h， 生成 17-Ethylendioxy-3-methoxy-oestra-2,5(10)-dien
  参考文献：
  名称：

  制备19-去甲-5(10)-雄烯酮化合物的方法

  摘要：

  本发明公开了一种制备19-去甲-5(10)-雄烯酮化合物的方法，以雌酚酮为原料，先依次通过醚化反应、缩酮保护反应、伯奇还原反应得到伯奇还原产物；然后用低级脂肪酸作为催化剂，将伯奇还原产物经选择性水解反应生成19-去甲-5(10)-雄烯酮化合物。本发明对17位有缩酮保护基的伯奇还原产物的水解工艺进行优化改良，以二元脂肪酸为酸催化剂，首次通过选择性水解反应高收率、高选择性地得到单一的19-去甲-5(10)-雄烯二酮；同时本发明也首次发现以低级一元脂肪酸为催化剂可以得到单一的19-去甲-5(10)-雄烯二酮的17位缩酮保护衍生物。

  公开号：

  CN103601781B

文献信息

• Steroid hormones—XVII
  作者：A.J. Birch、G.S.R. Subba Rao

  DOI：10.1016/s0040-4020(01)99124-0

  日期：1966.1

  Addition of dibromocarbene to the dihydrooestrone derivative (I) gives different mixtures of stereoisomeric products (II) according to conditions. One series is readily converted directly into tropones by the action of silver salts, the other indirectly by initial reaction with pyridine. The bis-adduct (III) has been converted into A-homotestosterone (VIII).

  根据条件，将二溴卡宾加到二氢雌酮衍生物（I）中得到不同的立体异构产物混合物（II）。一个系列很容易通过银盐的作用直接转化为托普酮，另一个系列则通过与吡啶的初始反应而间接转化为托克酮。该双加合物（III）已被转化为A-同型睾丸激素（VIII）。
• METHODS FOR PREPARING SYNTHETIC BILE ACIDS AND COMPOSITIONS COMPRISING THE SAME
  申请人：Moriarty Robert M.

  公开号：US20130261317A1

  公开（公告）日：2013-10-03

  This invention relates generally to methods for preparing certain bile acids from non-mammalian sourced starting materials as well as to synthetic bile acids and compositions comprising such acids wherein the acids are characterized by a different C 14 population than naturally occurring bile acids as well as being free from any mammalian pathogens. This invention is also directed to the synthesis of intermediates useful in the synthesis of such bile acids. Accordingly, the C ring of the steroidal scaffold is oxidized to provide a synthetic route and intermediates to DCA. This invention also provides synthetic methods for preparing deoxycholic acid or a salt thereof starting from aromatic steroids such as estrogen, equilenin, and derivatives thereof. This invention is also directed to intermediates such as 12-oxo or delta-9,11-ene steroids as well as novel processes for their preparation. In preferred embodiments, bile acids are provided herein which have substituents on the B-ring and/or D-ring side chain and optionally on the hydroxy group of the A-ring.

  本发明涉及从非哺乳动物来源的起始材料制备某些胆汁酸的方法，以及合成胆汁酸和包含这些酸的组合物，其中这些酸的特征是具有与自然存在的胆汁酸不同的C14种群，并且不含任何哺乳动物病原体。本发明还涉及合成在合成这种胆汁酸中有用的中间体。因此，甾体骨架的C环被氧化以提供合成路线和到DCA的中间体。本发明还提供了用芳香族类固醇（如雌激素、雌烯酮及其衍生物）起始制备脱氧胆酸或其盐的合成方法。本发明还涉及12-氧代或δ-9,11-烯类固醇等中间体以及其制备的新型过程。在首选实施例中，本发明提供了具有B环和/或D环侧链以及可选地具有A环羟基上取代基的胆汁酸。
• ANGIOGENESIS INHIBITORS
  申请人：Corey Elias James

  公开号：US20120190659A1

  公开（公告）日：2012-07-26

  Compounds of Structural Formula I or pharmaceutically acceptable salts thereof, are effective inhibitors of angiogenesis:

  结构式I的化合物或其药学上可接受的盐，是有效的抑制血管生成的抑制剂：
• Discovery of Potent and Practical Antiangiogenic Agents Inspired by Cortistatin A
  作者：Barbara Czakó、László Kürti、Akiko Mammoto、Donald E. Ingber、E. J. Corey

  DOI：10.1021/ja902601e

  日期：2009.7.1

  The discovery that cortistatins A and J show noteworthy antiangiogenic activity prompted an investigation of the possibility that simpler and much more easily made compounds based on a steroid core might have useful bioactivity. These studies have led to the development of several potent, water-soluble compounds that may be suitable for local application to treat ocular wet macular degeneration, an important cause of blindness, as well as for treatment of various other angiogenesis-dependent diseases. One of these substances was tested in a mouse retinal angiogenesis model and found to inhibit angiogenesis at a locally administered dose of 500 pmol. Comparison of cell migration data for this and two other synthetic compounds with published data on cortistatin A indicate that they inhibit vascular endothelial growth factor-induced cell migration of human umbilical vein endothelial cells more strongly than cortistatin A.
• [EN] ANGIOGENESIS INHIBITORS<br/>[FR] INHIBITEURS DE L'ANGIOGENÈSE
  申请人：HARVARD COLLEGE

  公开号：WO2010123545A3

  公开（公告）日：2011-02-03